CEMIP and myeloid sarcoma: Further research is needed to determine whether a therapeutic intervention aimed at decreasing KIAA1199 would help promote remyelination, as KIAA1199-driven HA degradation may be a key event promoting OPC maturation and enhancing myelin repair in MS.